Column Capital Advisors’s Biogen BIIB Stock Holding History

Column Capital Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$514	Sell	2 -9	-82%	-$2.41K	﹤0.01%	753
2023 Q2	$3.13K	Hold	11	–	–	﹤0.01%	673
2023 Q1	$3.06K	Hold	11	–	–	﹤0.01%	688
2022 Q4	$3.05K	Hold	11	–	–	﹤0.01%	666
2022 Q3	$3K	Hold	11	–	–	﹤0.01%	587
2022 Q2	$2K	Hold	11	–	–	﹤0.01%	624
2022 Q1	$2K	Sell	11 -35	-76%	-$7.61K	﹤0.01%	639
2021 Q4	$11K	Hold	46	–	–	﹤0.01%	495
2021 Q3	$13K	Sell	46 -1	-2%	-$328	﹤0.01%	432
2021 Q2	$16K	Sell	47 -175	-79%	-$53K	﹤0.01%	407
2021 Q1	$62K	Hold	222	–	–	0.01%	234
2020 Q4	$54K	Hold	222	–	–	0.01%	254
2020 Q3	$63K	Hold	222	–	–	0.02%	212
2020 Q2	$59K	Sell	222 -2	-0.9%	-$601	0.02%	222
2020 Q1	$71K	Hold	224	–	–	0.03%	156
2019 Q4	$66K	Buy	+224	New	+$62.2K	0.03%	194

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Column Capital Advisors's BIIB Position: Q3 2023 in Review

Column Capital Advisors reduced its Biogen (BIIB) stake by 82% in Q3 2023, selling an estimated $2.41K and leaving 2 shares worth $514. The position accounts for ﹤0.01% of the portfolio, ranked #753.

Column Capital Advisors first reported a position in BIIB in Q4 2019 and has held it in 16 quarters since. The position peaked at $71K in Q1 2020. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Column Capital Advisors held 2 shares of Biogen worth $514 as of Q3 2023.
Column Capital Advisors sold 9 Biogen shares in Q3 2023, an estimated $2.41K.
Biogen made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #753 holding.
Column Capital Advisors first reported a position in Biogen in Q4 2019 and has held it in 16 quarters since.
Column Capital Advisors's Biogen position peaked at $71K in Q1 2020.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.